Product image of Incellipan (Sorbitan Trioleate, Polysorbate 80, Sodium Citrate, Squalene, Citric Acid, Influenza Virus A/Turkey/) supplied by GNH India

Incellipan

Active Ingredient:
Sorbitan Trioleate, Polysorbate 80, Sodium Citrate, Squalene, Citric Acid, Influenza Virus A/Turkey/
Origin:
EU

Incellipan (Sorbitan Trioleate, Polysorbate 80, Sodium Citrate, Squalene, Citric Acid, Influenza Virus A/Turkey/)

Influenza vaccine, the active ingredient in Incellipan, is a vaccine presented as an injectable solution for intramuscular use. It stimulates the immune system to produce antibodies against influenza virus antigens, providing protective immunity against influenza infection in individuals at risk.

GNH India supplies Incellipan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable cold‑chain logistics for vaccine distribution, ensuring product integrity from manufacture to end‑user globally.

Manufacturer / TM Owner

Seqirus Netherlands B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Incellipan is an influenza vaccine used to prevent influenza infection across various population groups.
  • Seasonal influenza: provides protective immunity against the annually circulating influenza strains.
  • Pandemic influenza: can be employed to induce immunity against newly emerging influenza A viruses when matched to the strain.
  • High‑risk populations (elderly, pregnant women, immunocompromised): reduces the likelihood of severe disease, hospitalization, and complications.
  • Healthcare workers: helps maintain workforce health during flu season by lowering infection rates.

How It Works

  • The vaccine contains inactivated influenza virus antigens derived from the A/Turkey strain together with adjuvant components such as sorbitan trioleate, polysorbate 80, sodium citrate, squalene and citric acid. After intramuscular injection, antigen‑presenting cells process the viral proteins and present them to T‑lymphocytes, initiating a humoral response that generates strain‑specific neutralising antibodies, thereby conferring protective immunity.

Side Effects

Incellipan, like other influenza vaccines, may be associated with a range of adverse reactions following injection.

Common Side Effects

  • Pain at injection site: mild to moderate soreness.
  • Redness or swelling at injection site.
  • Low‑grade fever.
  • Headache.
  • Myalgia.
  • Fatigue.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare neurological disorder with progressive weakness.
  • Seizures: infrequent occurrence, especially in children with fever.
  • Thrombocytopenia: low platelet count.

Precautions & Warnings

  • Before administering Incellipan, healthcare professionals should observe the following precautions to ensure safe use.
  • Assess allergy history: confirm no previous severe reaction to influenza vaccines or any component.
  • Evaluate immune status: consider reduced efficacy in immunocompromised patients.
  • Defer vaccination during acute moderate or severe illness: postpone until recovery.
  • Monitor for fever in children under 5: observe for high temperature post‑vaccination.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Incellipan may interact with certain medical conditions or concomitant therapies; relevant interactions are grouped below.

Major Interactions (Avoid)

  • Live attenuated vaccines: avoid simultaneous administration due to potential interference with immune response.
  • Immunosuppressive therapy (e.g., high‑dose steroids, chemotherapy): may diminish vaccine efficacy and increase risk of infection.
  • Severe allergic reaction to any vaccine component: contraindicates use.

Moderate Interactions (Monitor Closely)

  • Antipyretics (acetaminophen, ibuprofen): may mask fever, but generally safe if needed.
  • Egg allergy: most influenza vaccines are low‑egg; monitor for reactions.
  • Chronic illnesses (e.g., asthma, COPD): observe for exacerbation post‑vaccination.

Frequently Asked Questions

Incellipan is an influenza vaccine indicated for the prevention of seasonal and pandemic influenza. It is administered to individuals at risk of infection, including the general population, high‑risk groups, and healthcare workers, to reduce the incidence of flu‑related illness.

The vaccine contains inactivated influenza virus antigens that, after intramuscular injection, are taken up by antigen‑presenting cells. These cells trigger a T‑cell‑dependent immune response, leading to the production of strain‑specific neutralising antibodies that protect against future exposure to the virus.

The dose of Incellipan is determined by the prescribing healthcare professional based on the patient’s age, health status, and local immunisation guidelines. The prescriber will select the appropriate volume and schedule for each individual.

Safety data for Incellipan in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits and risks before vaccinating pregnant or breastfeeding individuals, following national recommendations and considering the risk of influenza infection.

To order Incellipan, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Incellipan is comparable to other inactivated influenza vaccines in terms of efficacy and safety profile. Differences may lie in the specific viral strains included, adjuvant composition, and manufacturing processes. Clinicians should review product specifications and local guidelines when selecting a vaccine.

Incellipan must be stored at 2‑8 °C, protected from light, and should never be frozen or shaken. The product should be kept in its original packaging until use to maintain stability and potency throughout the cold‑chain distribution.

Incellipan is given as a single intramuscular injection, typically into the deltoid muscle of the upper arm. The administration technique follows standard vaccination practices, and the injection site should be observed for any immediate reactions.

Serious but rare risks include anaphylaxis, Guillain‑Barré syndrome, seizures, and thrombocytopenia. Patients should be monitored after vaccination, and any signs of severe allergic reaction or neurological symptoms should receive immediate medical attention.

Individuals with a known severe allergy to any component of the vaccine, or who have experienced a previous severe reaction to an influenza vaccine, should not receive Incellipan. Additionally, those with uncontrolled acute illness should defer vaccination until recovery.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Sorbitan Trioleate, Polysorbate 80, Sodium Citrate, Squalene, Citric Acid, Influenza Virus A/Turkey/

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT